Trastuzumab-based combination therapy for breast cancer.
about
Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study.Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison.Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumabThe vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer.Underuse of anthracyclines in women with HER-2+ advanced breast cancer.Controversies in breast cancer: adjuvant and neoadjuvant therapy.Research progress on criteria for discontinuation of EGFR inhibitor therapy.A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancerThe small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell linesRecurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.A comparative study on the physicochemical and biological stability of IgG1 and monoclonal antibodies during spray drying processBiomarkers of drugs targeting HER-family signalling in cancer.Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
P2860
Q33236634-95EC5D20-228D-4F74-A6C3-F5F9F12D8EB7Q33354783-E5EF4103-660F-4D95-A41F-C04CCB784292Q33528162-E272D978-BA6C-4555-B0CF-6112DAD3F651Q35234716-FF06FFDF-ECC9-4282-8113-E60136C63BBEQ35555254-BEFA72A4-355F-40F6-B225-B17F8AFC038DQ35584166-848A94AA-4BEE-4AF1-8E2F-B80E8A452E6CQ36163952-73D547DC-0588-480D-857B-61561DACA19FQ36330264-27B1E9AA-D6BC-47C8-9D0A-72EC41F2CD47Q36616632-699ED0C0-90C3-4A3C-AF0E-3FE96C472346Q36677504-E9DE22D3-93D5-4E6F-A3EA-DE120EE46683Q36717363-59933AB1-1AC1-4A7E-96C9-27B7783C3022Q36753310-99A9C017-0182-49DF-939B-AF749AF1D846Q37164587-725377C1-D6A4-4911-AEBE-3D1D4C2827EDQ37679799-D851138D-D141-403C-9119-36FBE5FAEBB7Q38150774-57003DCD-C641-4365-8DF7-BE9EF4A44B98Q42659769-A1912FBD-A157-404C-A3EE-FFBB394C609C
P2860
Trastuzumab-based combination therapy for breast cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Trastuzumab-based combination therapy for breast cancer.
@ast
Trastuzumab-based combination therapy for breast cancer.
@en
type
label
Trastuzumab-based combination therapy for breast cancer.
@ast
Trastuzumab-based combination therapy for breast cancer.
@en
prefLabel
Trastuzumab-based combination therapy for breast cancer.
@ast
Trastuzumab-based combination therapy for breast cancer.
@en
P2093
P2860
P356
P1476
Trastuzumab-based combination therapy for breast cancer.
@en
P2093
Filippo Montemurro
Giorgio Valabrega
Massimo Aglietta
P2860
P356
10.1517/14656566.5.1.81
P407
P577
2004-01-01T00:00:00Z